Claude Hariton

Ph.D., D.Sc.

Vice President, Chief Scientific Officer (CSO)

Dr Hariton received his PhD in neurosciences from the University of Sciences in Marseille, France, in 1984, and conducted postdoctoral studies at the French National Institute of Health and Medical Research (INSERM) U278 in Marseille and the Neurochemistry Center of the National Center for Scientific Research (CNRS) in Strasbourg. He received his DSc in Pharmacology from the University of Medicine in Marseille, France, in 1988 while leading drug development in ophthalmology at Ciba Geigy then Novartis in Switzerland. Dr Hariton was recently the Global Head of Research and Development at Advanced Accelerator Applications (AAA), a pharmaceutical company spin of from the European Organization for Nuclear Research (CERN) and specializing in nuclear medicine. He joined AAA in 2014 and led the development and registration of key products, contributing to the listing of the company on the US stock exchange (NASDAQ) in 2015, prior to Novartis acquisition of the company end of 2017. Over the past 25 years, he has held senior management functions in biotechnology and pharmaceutical companies in Switzerland, Canada, Australia, Germany, Spain and the United Kingdom, with his most recent positions including Vice President Regulatory Affairs and Drug Safety (Mayne Pharma), Vice President, Clinical and Regulatory Affairs and Chief Medical Officer (Aeterna-Zentaris), Vice President, Scientific Affairs (Fresenius) and Global Head of Research and Development (ISDIN).